Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) (TgCDPK1)

Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) is a vital enzyme in the life cycle of the protozoan parasite Toxoplasma gondii, the causative agent of toxoplasmosis [1, 2]. It serves as a master regulator of calcium-mediated signaling, specifically controlling the exocytosis of micronemes—specialized secretory organelles essential for parasite motility, host-cell invasion, and egress [5, 9]. As an obligate intracellular pathogen, T. gondii relies on these processes to propagate and cause disease, making TgCDPK1 an attractive therapeutic target [4, 11]. The enzyme is characterized by a unique ATP-binding pocket containing a small glycine gatekeeper residue (Gly128), a feature absent in all known human kinases, which typically possess larger gatekeeper residues like methionine or phenylalanine [4, 6, 10]. This structural divergence allows for the development of highly selective bumped kinase inhibitors (BKIs) that potently inhibit the parasite enzyme while sparing host kinases, thereby minimizing toxicity [1, 4, 12]. Research into TgCDPK1 inhibitors aims to address clinical challenges such as toxoplasmic encephalitis in immunocompromised individuals and congenital toxoplasmosis [1, 12]. Furthermore, the absence of this kinase family in mammalian hosts enhances its potential as a safe drug target for long-term treatment [5, 9]. Ongoing studies focus on optimizing these inhibitors for better central nervous system penetration and reduced off-target effects like hERG inhibition [11, 12].

Other names

CDPK1Calcium-dependent protein kinase 1TGGT1_301440

ATP-competitive inhibition of the kinase activity, specifically targeting the unique glycine gatekeeper residue to block calcium-mediated microneme secretion and parasite motility [1, 4, 11].